FocalTherics (NASDAQ:FOCL) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded FocalTherics from “sell” to “hold.” Across analysts, the stock has a “Moderate Buy” consensus rating and an average price target of $9.67, though recommendations and targets vary widely.
• FocalTherics reported a quarterly loss of $0.10 per share, beating estimates of a $0.18 loss, on revenue of $9.83 million. Analysts expect a full-year loss of $0.82 per share.
• Company insiders bought 116,000 shares worth a total of $551,000 over the past 90 days.

FocalTherics (NASDAQ:FOCL - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms have also recently issued reports on FOCL. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, August 25th. Piper Sandler reiterated a "neutral" rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday, August 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of FocalTherics in a report on Monday, August 17th. Finally, Mizuho initiated coverage on shares of FocalTherics in a research report on Friday, July 17th. They set an "outperform" rating and a $15.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, FocalTherics presently has an average rating of "Moderate Buy" and an average price target of $9.67.

FocalTherics Stock Performance

NASDAQ FOCL opened at $3.32 on Friday. The business has a 50-day moving average of $4.23. The company has a current ratio of 1.60, a quick ratio of 1.38 and a debt-to-equity ratio of 1.79. FocalTherics has a 12 month low of $1.82 and a 12 month high of $6.40.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.08. The company had revenue of $9.83 million for the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. As a group, equities research analysts expect that FocalTherics will post -0.82 earnings per share for the current year.

Insider Buying and Selling

In other FocalTherics news, Director Fran Schulz bought 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, with a total value of $47,500.00. Following the acquisition, the director directly owned 15,100 shares of the company's stock, valued at $71,725. The trade was a 196.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David R. Horn acquired 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The stock was acquired at an average price of $4.75 per share, with a total value of $47,500.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $47,500. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 116,000 shares of company stock valued at $551,000 in the last ninety days. Company insiders own 10.10% of the company's stock.

Institutional Investors Weigh In On FocalTherics

An institutional investor recently bought a new stake in FocalTherics stock. Lido Advisors LLC purchased a new stake in shares of FocalTherics (NASDAQ:FOCL - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,654 shares of the company's stock, valued at approximately $40,000. Institutional investors own 62.74% of the company's stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.